Goldman Sachs’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-131,984
| Closed | -$1.98M | – | 7380 |
|
|
2016
Q2 | $1.98M | Sell |
131,984
-35,994
| -21% | -$462K | ﹤0.01% | 3632 |
|
|
2016
Q1 | $2.04M | Buy |
167,978
+51,622
| +44% | +$724K | ﹤0.01% | 3446 |
|
|
2015
Q4 | $1.85M | Sell |
116,356
-25,977
| -18% | -$409K | ﹤0.01% | 3701 |
|
|
2015
Q3 | $2.18M | Sell |
142,333
-104,264
| -42% | -$2.25M | ﹤0.01% | 3697 |
|
|
2015
Q2 | $6M | Buy |
246,597
+51,539
| +26% | +$1.23M | ﹤0.01% | 2812 |
|
|
2015
Q1 | $4.54M | Buy |
195,058
+73,226
| +60% | +$1.94M | ﹤0.01% | 2993 |
|
|
2014
Q4 | $3.06M | Buy |
121,832
+114,246
| +1,506% | +$3.35M | ﹤0.01% | 3436 |
|
|
2014
Q3 | $236K | Sell |
7,586
-179,849
| -96% | -$4.87M | ﹤0.01% | 6004 |
|
|
2014
Q2 | $4.85M | Sell |
187,435
-317,904
| -63% | -$7.06M | ﹤0.01% | 3076 |
|
|
2014
Q1 | $11.8M | Sell |
505,339
-50,573
| -9% | -$1.11M | ﹤0.01% | 2220 |
|
|
2013
Q4 | $14.1M | Buy |
555,912
+24,864
| +5% | +$561K | ﹤0.01% | 2045 |
|
|
2013
Q3 | $10.8M | Buy |
531,048
+109,768
| +26% | +$2.44M | ﹤0.01% | 2167 |
|
|
2013
Q2 | $8.84M | Buy |
+421,280
| New | +$7.53M | ﹤0.01% | 2203 |
|
Goldman Sachs's SGNT Position: Q3 2016 in Review
Goldman Sachs sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 131,984 shares — an estimated $1.98M sold.
Goldman Sachs first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $14.1M in Q4 2013. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- Goldman Sachs reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- Goldman Sachs sold 131,984 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $1.98M.
- Goldman Sachs first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- Goldman Sachs's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $14.1M in Q4 2013.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on Goldman Sachs's 13F filing for Q3 2016, filed 14 Nov 2016.